全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Low-Flow Polysulfone Hemodialysis Alters Lipoprotein Parameters, Paraoxonase Activity and in Vitro Incorporation of Phospholipids

DOI: 10.4236/jbpc.2017.83003, PP. 23-38

Keywords: Hemodialysis, Dyslipidemia, Cardiovascular Risk Bioindices, PLTP, PON-1, HDL-Remodeling, Low-Flow Polysulfone Dialyzing-Membrane

Full-Text   Cite this paper   Add to My Lib

Abstract:

End stage-renal-disease (ESRD) is associated with dyslipidemia and premature atherosclerosis. The study evaluates the effect of hemodialysis (HD) on HDL-remodeling between pre- and post-HD. Was conducted a cross-sectional study with 50 ESRD male patients, undergoing HD at Ana Neri Hospital, Salvador, Brazil. All individuals were on HD for at least 3 months, into a three sessions protocol for 3 - 4 hours per week, with a polysulfone low-flow basic-dialyzing-membrane and unfractionated-heparin. HDL Phospholipid-incorporation was measured by 14C-PL-scintillation-counting, expressed as %14C-PL/mL/hour. Paraoxonase (PON-1) activity was measured by spectrophotometry using paraoxon as substrate. Cardiovascular risk ratios and atherogenic index of plasma were calculated. Total cholesterol, HDL-C and non-HDL-C increased at post-HD on all age groups, but without triglycerides (TG) changes. TG/HDL-C decreased in 30 - 39 and 40 - 49 year (y) at post-HD (p < 0.05). LDL-C/apoB increased in >60 y, after HD (p <

 References

[1]  Schlitt, A., Heine, G.H., Jiang, X.C., Messow, M., Blankenberg, S., Rupprecht, H.J., et al. (2007) Phospholipid Transfer Protein in Hemodialysis Patients. American Journal of Nephrology, 27, 138-143.
https://doi.org/10.1159/000099943
[2]  Shoji, T., Abe, T., Matsuo, H., Egusa, G., Yamasaki, Y., Kashihara, N., et al. (2011) Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 19, 299-315.
https://doi.org/10.5551/jat.10454
[3]  Gugliucci, A., Mehlhaff, K., Kinugasa, E., Ogata, H., Hermo, R., Schulze, J., et al. (2007) Paraoxonase-1 Concentrations in End-Stage Renal Disease Patients Increase after Hemodialysis: Correlation with Low Molecular AGE Adduct Clearance. Clinica Chimica Acta, 377, 213-220.
https://doi.org/10.1016/j.cca.2006.09.028
[4]  Yamamoto, S. and Kon, V. (2009) Mechanisms for Increased Cardiovascular Disease in Chronic Kidney Dysfunction. Current Opinion in Nephrology and Hypertension, 18, 181-188.
https://doi.org/10.1097/MNH.0b013e328327b360
[5]  Mitwalli, A.H., Alam, A.A., Al Wakeel, J.S. and Isnani, A.C. (2011) Dyslipidemia in Dialysis Patients. Saudi Journal of Kidney Diseases and Transplantation, 22, 689-694.
[6]  Chmielewski, M., Carrero, J.J., Nordfors, L., Lindholm, B. and Stenvinkel, P. (2008) Lipid Disorders in Chronic Kidney Disease: Reverse Epidemiology and Therapeutic Approach. Journal of Nephrology, 21, 635-644.
[7]  Lacquaniti, A., Bolignano, D., Donato, V., Bono, C., Fazio, M.R. and Buemi, M. (2010) Alterations of Lipid Metabolism in Chronic Nephropathies: Mechanisms, Diagnosis and Treatment. Kidney & Blood Pressure Research, 33, 100-110.
https://doi.org/10.1159/000302712
[8]  Jung, K., Scheifler, A., Schulze, B.D. and Scholz, M. (1995) Lower Serum High-Density Lipoprotein-Cholesterol Concentration in Patients Undergoing Maintenance Hemodialysis with Acetate than with Bicarbonate. American Journal of Kidney Diseases, 25, 584-588.
https://doi.org/10.1016/0272-6386(95)90127-2
[9]  Abo-Zenah, H., Sabry, A., Farouk, A., Abdelhalim, N., El-Sayed, K. and Sobh, M. (2007) The Impact of Haemodialysis-Associated Variables on Lipid Profile in Egyptian Haemodialysis Population. International Urology and Nephrology, 39, 609-618.
https://doi.org/10.1007/s11255-006-9162-x
[10]  Cacciagiu, L.D., Gonzalez, A.I., Gomez Rosso, L., Merono, T., De Marziani, G., Elbert, A., et al. (2012) HDL-Associated Enzymes and Proteins in Hemodialysis Patients. Clinical Biochemistry, 45, 243-248.
https://doi.org/10.1016/j.clinbiochem.2011.12.008
[11]  Oka, T., Kujiraoka, T., Ito, M., Egashira, T., Takahashi, S., Nanjee, M.N., et al. (2000) Distribution of Phospholipid Transfer Protein in Human Plasma: Presence of Two Forms of Phospholipid Transfer Protein, One Catalytically Active and the Other Inactive. The Journal of Lipid Research, 41, 1651-1657.
[12]  Masson, D., Deckert, V., Gautier, T., Klein, A., Desrumaux, C., Viglietta, C., et al. (2011) Worsening of Diet-Induced Atherosclerosis in a New Model of Transgenic Rabbit Expressing the Human Plasma Phospholipid Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 766-774.
https://doi.org/10.1161/ATVBAHA.110.215756
[13]  vanHaperen, R., van Tol, A., van Gent, T., Scheek, L., Visser, P., van der Kamp, A., et al. (2002) Increased Risk of Atherosclerosis by Elevated Plasma Levels of Phospholipid Transfer Protein. The Journal of Biological Chemistry, 277, 48938-48943.
https://doi.org/10.1074/jbc.M209128200
[14]  Attia, N., Domingo, N., Lorec, A.M., Nakbi, A., Hammami, S., Ben Hamda, K., et al. (2009) Reverse Modulation of the HDL Anionic Peptide Factor and Phospholipid Transfer Protein Activity in Coronary Artery Disease and Type 2 Diabetes Mellitus. Clinical Biochemistry, 42, 845-851.
https://doi.org/10.1016/j.clinbiochem.2008.12.008
[15]  Superko, H.R. (2009) Cardiovascular Event Risk: High-Density Lipoprotein and Paraoxonase. Journal of the American College of Cardiology, 54, 1246-1248.
https://doi.org/10.1016/j.jacc.2009.07.006
[16]  Gugliucci, A., Kinugasa, E., Kotani, K., Caccavello, R. and Kimura, S. (2011) Serum Paraoxonase 1 (PON1) Lactonase Activity Is Lower in End-Stage Renal Disease Patients than in Healthy Control Subjects and Increases after Hemodialysis. Clinical Chemistry and Laboratory Medicine, 49, 61-67.
https://doi.org/10.1515/CCLM.2011.004
[17]  Xavier, H.T., Izar, M.C., FariaNeto, J.R., Assad, M.H., Rocha, V.Z., Sposito, A.C., et al. (2013) V Brazilian Guideline for Dyslipidemia and Atherosclerosis Prevention: Department of Atherosclerosis of Brazilian Society of Cardiology. Arquivos Brasileiros de Cardiologia, 101, 22.
[18]  Senti, M., Tomas, M., Fito, M., Weinbrenner, T., Covas, M.I., Sala, J., et al. (2003) Antioxidant Paraoxonase 1 Activity in the Metabolic Syndrome. The Journal of Clinical Endocrinology & Metabolism, 88, 5422-5426.
https://doi.org/10.1210/jc.2003-030648
[19]  Cabarkapa, V., Djeric, M., Stosic, Z., Sakac, V., Lozanov-Crvenkovic, Z. and Vuckovic, B. (2012) Evaluation of Lipid Parameters and Bioindices in Patients with Different Stages of Chronic Renal Failure. Vojnosanitetski Pregled, 69, 961-966.
https://doi.org/10.2298/VSP1211961C
[20]  Rajkovic, M.G., Rumora, L., Juretic, D., Grubisic, T.Z., Flegar-Mestric, Z., Vrkic, N., et al. (2010) Effect of Non-Genetic Factors on Paraoxonase 1 Activity in Patients Undergoing Hemodialysis. Clinical Biochemistry, 43, 1375-1380.
https://doi.org/10.1016/j.clinbiochem.2010.08.024
[21]  Kennedy, D.J., Tang, W.H., Fan, Y., Wu, Y., Mann, S., Pepoy, M., et al. (2013) Diminished Antioxidant Activity of High-Density Lipoprotein-Associated Proteins in Chronic Kidney Disease. Journal of the American Heart Association, 2, e000104.
https://doi.org/10.1161/JAHA.112.000104
[22]  Schiavon, R., De Fanti, E., Giavarina, D., Biasioli, S., Cavalcanti, G. and Guidi, G. (1996) Serum Paraoxonase Activity Is Decreased in Uremic Patients. Clinica Chimica Acta, 247, 71-80.
https://doi.org/10.1016/0009-8981(95)06221-1
[23]  Camps, J., Garcia-Heredia, A., Rull, A., Alonso-Villaverde, C., Aragones, G., Beltran-Debon, R., et al. (2012) PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways. PPAR Research, 2012, Article ID: 616371.
https://doi.org/10.1155/2012/616371
[24]  Gugliucci, A., Kotani, K. and Kimura, S. (2012) Paraoxonase 1 in Chronic Kidney Failure. Journal of Lipids, 2012, Article ID: 726048.
https://doi.org/10.1155/2012/726048
[25]  Yan, D., Navab, M., Bruce, C., Fogelman, A.M. and Jiang, X.C. (2004) PLTP Deficiency Improves the Anti-Inflammatory Properties of HDL and Reduces the Ability of LDL to Induce Monocyte Chemotactic Activity. The Journal of Lipid Research, 45, 1852-1858.
https://doi.org/10.1194/jlr.M400053-JLR200
[26]  Schlitt, A., Liu, J., Yan, D., Mondragon-Escorpizo, M., Norin, A.J. and Jiang, X.C. (2005) Anti-Inflammatory Effects of Phospholipid Transfer Protein (PLTP) Deficiency in Mice. Biochimica et Biophysica Acta, 1733, 187-191.
https://doi.org/10.1016/j.bbalip.2004.12.011
[27]  Cheung, M.C., Wolfbauer, G., Brown, B.G. and Albers, J.J. (1999) Relationship between Plasma Phospholipid Transfer Protein Activity and HDL Subclasses among Patients with Low HDL and Cardiovascular Disease. Atherosclerosis, 142, 201-205.
https://doi.org/10.1016/S0021-9150(98)00190-7
[28]  Cheung, M.C., Brown, B.G., Marino Larsen, E.K., Frutkin, A.D., O'Brien, K.D. and Albers, J.J. (2006) Phospholipid Transfer Protein Activity Is Associated with Inflammatory Markers in Patients with Cardiovascular Disease. Biochimica et Biophysica Acta, 1762, 131-137.
https://doi.org/10.1016/j.bbadis.2005.09.002
[29]  Pahl, M.V., Ni, Z., Sepassi, L., Moradi, H. and Vaziri, N.D. (2009) Plasma Phospholipid Transfer Protein, Cholesteryl Ester Transfer Protein and Lecithin:Cholesterol Acyltransferase in End-Stage Renal Disease (ESRD). Nephrology Dialysis Transplantation, 24, 2541-2546.
https://doi.org/10.1093/ndt/gfp120
[30]  Huang, F., Yang, Z., Xu, B., Bi, Y., Xu, M., Xu, Y., et al. (2013) Both Serum Apolipoprotein B and the Apolipoprotein B/Apolipoprotein A-I Ratio Are Associated with Carotid Intima-Media Thickness. PLoS ONE, 8, e54628.
https://doi.org/10.1371/journal.pone.0054628
[31]  Walldius, G., Jungner, I., Aastveit, A.H., Holme, I., Furberg, C.D. and Sniderman, A.D. (2004) The apoB/apoA-I Ratio Is Better than the Cholesterol Ratios to Estimate the Balance between Plasma Proatherogenic and Antiatherogenic Lipoproteins and to Predict Coronary Risk. Clinical Chemistry and Laboratory Medicine, 42, 1355-1363.
https://doi.org/10.1515/CCLM.2004.254
[32]  Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., Drexel, H., et al. (2016) ESC/EAS Guidelines for the Management of Dyslipidaemias the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)—Developed with the Special Contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 1-72. [In Press]
[33]  Peters, A.L. (2008) Clinical Relevance of Non-HDL Cholesterol in Patients with Diabetes. Clinical Diabetes, 26, 3-7.
https://doi.org/10.2337/diaclin.26.1.3
[34]  Holman, R.R., Coleman, R.L., Shine, B.S. and Stevens, R.J. (2005) Non-HDL Cholesterol Is Less Informative than the Total-to-HDL Cholesterol Ratio in Predicting Cardiovascular Risk in Type 2 Diabetes. Diabetes Care, 28, 1796-1797.
https://doi.org/10.2337/diacare.28.7.1796
[35]  Eliasson, B., Cederholm, J., Eeg-Olofsson, K., Svensson, A.M., Zethelius, B. and Gudbjornsdottir, S. (2011) Clinical Usefulness of Different Lipid Measures for Prediction of Coronary Heart Disease in Type 2 Diabetes: A Report from the Swedish National Diabetes Register. Diabetes Care, 34, 2095-2100.
https://doi.org/10.2337/dc11-0209
[36]  Kimak, E., Halabis, M., Baranowicz-Gaszczyk, I., Solski, J. and Ksiazek, A. (2011) Association between Moderately Oxidized Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclass Distribution in Hemodialyzed and Post-Renal Transplant Patients. Journal of Zhejiang University Science B, 12, 365-371.
https://doi.org/10.1631/jzus.B1000348
[37]  Settasatian, N., Duong, M., Curtiss, L.K., Ehnholm, C., Jauhiainen, M., Huuskonen, J., et al. (2001) The Mechanism of the Remodeling of High Density Lipoproteins by Phospholipid Transfer Protein. The Journal of Biological Chemistry, 276, 26898-26905.
https://doi.org/10.1074/jbc.M010708200
[38]  van Haperen, R., van Tol, A., Vermeulen, P., Jauhiainen, M., van Gent, T., van den Berg, P., et al. (2000) Human Plasma Phospholipid Transfer Protein Increases the Antiatherogenic Potential of High Density Lipoproteins in Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1082-1088.
https://doi.org/10.1161/01.ATV.20.4.1082
[39]  Yazdanyar, A., Yeang, C. and Jiang, X.-C. (2011) Role of Phospholipid Transfer Protein in High-Density Lipoprotein-Mediated Reverse Cholesterol Transport. Current Atherosclerosis Reports, 13, 242-248.
https://doi.org/10.1007/s11883-011-0172-5
[40]  Dullaart, R.P., van Tol, A. and Dallinga-Thie, G.M. (2013) Phospholipid Transfer Protein, an Emerging Cardiometabolic Risk Marker: Is It Time to Intervene? Atherosclerosis, 228, 38-41.
https://doi.org/10.1016/j.atherosclerosis.2013.01.043
[41]  Tsimihodimos, V., Mitrogianni, Z. and Elisaf, M. (2011) Dyslipidemia Associated with Chronic Kidney Disease. Open Cardiovascular Medicine Journal, 5, 41-48.
https://doi.org/10.2174/1874192401105010041
[42]  Tsunoda, F., Koba, S., Hirano, T., Ban, Y., Iso, Y., Suzuki, H., et al. (2004) Association between Small Dense Low-Density Lipoprotein and Postprandial Accumulation of Triglyceride-Rich Remnant-Like Particles in Normotriglyceridemic Patients with Myocardial Infarction. Circulation Journal, 68, 1165-1172.
https://doi.org/10.1253/circj.68.1165
[43]  Koba, S., Hirano, T., Murayama, S., Kotani, T., Tsunoda, F., Iso, Y., et al. (2003) Small Dense LDL Phenotype Is Associated with Postprandial Increases of Large VLDL and Remnant-Like Particles in Patients with Acute Myocardial Infarction. Atherosclerosis, 170, 131-140.
https://doi.org/10.1016/S0021-9150(03)00245-4
[44]  Da Luz, P.L., Favarato, D., Faria-Neto Junior, J.R., Lemos, P. and Chagas, A.C.P. (2008) High Ratio of Triglycerides to HDL-Cholesterol Predicts Extensive Coronary Disease. Clinics, 63, 427-432.
https://doi.org/10.1590/S1807-59322008000400003
[45]  Rizzo, M., Barbagallo, C.M., Severino, M., Polizzi, F., Onorato, F., Noto, D., et al. (2003) Low-Density-Lipoprotein Peak Particle Size in a Mediterranean Population. European Journal of Clinical Investigation, 33, 126-133.
https://doi.org/10.1046/j.1365-2362.2003.01125.x
[46]  Tani, S., Saito, Y., Anazawa, T., Kawamata, H., Furuya, S., Takahashi, H., et al. (2011) Low-Density Lipoprotein Cholesterol/Apolipoprotein B Ratio May Be a Useful Index That Differs in Statin-Treated Patients with and without Coronary Artery Disease: A Case Control Study. International Heart Journal, 52, 343-347.
https://doi.org/10.1536/ihj.52.343
[47]  Erdur, M.F., Tonbul, H.Z., Ozbiner, H., Ozcicek, A., Ozcicek, F., Akbas, E.M., et al. (2013) The Relationship between Atherogenic Index of Plasma and Epicardial Adipose Tissue in Hemodialysis and Peritoneal Dialysis Patients. Renal Failure, 35, 1193-1198.
https://doi.org/10.3109/0886022X.2013.823826
[48]  Yildiz, G., Duman, A., Aydin, H., Yilmaz, A., Hur, E., Magden, K., et al. (2013) Evaluation of Association between Atherogenic Index of Plasma and Intima-Media thickness of the Carotid Artery for Subclinic Atherosclerosis in Patients on Maintenance Hemodialysis. Hemodialysis International, 17, 397-405.
https://doi.org/10.1111/hdi.12041
[49]  Holmes, D.T., Frohlich, J. and Buhr, K.A. (2008) The Concept of Precision Extended to the Atherogenic Index of Plasma. Clinical Biochemistry, 41, 631-635.
https://doi.org/10.1016/j.clinbiochem.2008.01.023
[50]  Yang, D., Liu, X. and Xiang, M. (2011) The Correlation between Lipids Ratio and Degree of Coronary Artery Stenosis. High Blood Pressure & Cardiovascular Prevention, 18, 53-56.
https://doi.org/10.2165/11593480-000000000-00000
[51]  Castelli, W.P., Abbott, R.D. and McNamara, P.M. (1983) Summary Estimates of Cholesterol Used to Predict Coronary Heart Disease. Circulation, 67, 730-734.
https://doi.org/10.1161/01.CIR.67.4.730
[52]  Camont, L., Chapman, M.J. and Kontush, A. (2011) Biological Activities of HDL Subpopulations and Their Relevance to Cardiovascular Disease. Trends in Molecular Medicine, 17, 594-603.
https://doi.org/10.1016/j.molmed.2011.05.013
[53]  Abbasi, A., Corpeleijn, E., Gansevoort, R.T., Gans, R.O., Hillege, H.L., Stolk, R.P., et al. (2013) Role of HDL Cholesterol and Estimates of HDL Particle Composition in Future Development of Type 2 Diabetes in the General Population: The PREVEND Study. The Journal of Clinical Endocrinology & Metabolism, 98, E1352-E1359.
https://doi.org/10.1210/jc.2013-1680
[54]  Fernandez, M.L., Jones, J.J., Ackerman, D., Barona, J., Calle, M., Comperatore, M.V., et al. (2010) Low HDL Cholesterol Is Associated with Increased Atherogenic Lipoproteins and Insulin Resistance in Women Classified with Metabolic Syndrome. Nutrition Research and Practice, 4, 492-498.
https://doi.org/10.4162/nrp.2010.4.6.492
[55]  Vekic, J., Kotur-Stevuljevic, J., Jelic-Ivanovic, Z., Spasic, S., Spasojevic-Kalimanovska, V., Topic, A., et al. (2007) Association of Oxidative Stress and PON1 with LDL and HDL Particle Size in Middle-Aged Subjects. European Journal of Clinical Investigation, 37, 715-723.
https://doi.org/10.1111/j.1365-2362.2007.01849.x

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133